Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis

Anal transitional zone dysplasia after stapled ileal pouch-anal anastomosis is infrequent, and usually self-limiting, finds a research team in the January issue of Diseases of the Colon and Rectum.

News image

fiogf49gjkf04

Stapling of the ileal pouch-anal anastomosis, with preservation of the anal transitional zone, remains controversial due to the potential risk of dysplasia and cancer.

However, natural history, and optimal treatment of anal transitional zone dysplasia, 10 or more years after surgery are unknown.

In this study, a research team from Cleveland, Ohio, established the risk of dysplasia in the anal transitional zone. They also assessed the outcome of a conservative management policy for anal transitional zone dysplasia, with a minimum of 10 years' follow-up after ileal pouch-anal anastomosis.

The team studied 289 patients undergoing anal transitional zone-sparing stapled ileal pouch-anal anastomosis for IBD, between 1986 and 1990.

They included 178 patients undergoing anal transitional zone-sparing ileal pouch-anal anastomosis, who were studied with serial anal transitional zone biopsies for at least 10 years, postoperatively.

Median follow-up was 130 months.

No cancer was found in the anal transitional zone during the study period.
Diseases of the Colon and Rectum

The researchers found that anal transitional zone dysplasia developed in 8 patients, between 4 and 123 months after surgery.

The team identified no association with gender, age, preoperative disease duration, or extent of colitis. However, the risk of anal transitional zone dysplasia was associated with cancer or dysplasia as a preoperative diagnosis, or in the proctocolectomy specimen.

Dysplasia was high grade in 2 patients and low grade in 6.

Of these, 2 patients with low-grade dysplasia, on 2 or more occasions after detection of low-grade dysplasia, underwent completion mucosectomy and perineal pouch advancement with neo-ileal pouch-anal anastomosis.

Of the patients with high-grade dysplasia, 1 was to undergo completion mucosectomy, however this was not found to be technically feasible. Instead, partial mucosectomy, with vigorous anal transitional zone biopsy, was performed with close postoperative surveillance. Biopsies were negative for dysplasia.

The second high-grade dysplasia underwent examination under anesthesia with negative anal transitional zone biopsies and will be kept under close surveillance.

The team found no cancer in the anal transitional zone during the study period.

The research team treated the 4 other patients with low-grade dysplasia expectantly, and have been dysplasia-free for a median of 119 months.

Dr Feza Remzi’s team concluded, “Anal transitional zone dysplasia after stapled ileal pouch-anal anastomosis is infrequent and is usually self-limiting”.

“Anal transitional zone preservation did not lead to the development of cancer in the anal transitional zone with a minimum of 10 years of follow-up.”

“Long-term surveillance is recommended to monitor dysplasia.”

“If repeat biopsy confirms persistent dysplasia, mucosectomy with perineal pouch advancement and neo-ileal pouch-anal anastomosis is recommended.”

Dis Colon Rectum 2003; 46(1): 6-13
22 January 2003

Go to top of page Email this page Email this page to a colleague

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA
 22 January 2018 
Improving symptoms in GERD
 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us